Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by MMABStraderon Jan 28, 2024 12:40pm
160 Views
Post# 35849287

RE:RE:RE:RE:RE:RE:Basher on Basher Bickering

RE:RE:RE:RE:RE:RE:Basher on Basher Bickering
In response to Geery's post... two reasons why 90 patients is important and why "it will" impact share price in a positive way.

First, Baxter is more than likely going to give Spectral a milestone payment once 90 is announced.  It certainly won't be less than their first payment of $5 million and will probably be some multiple of $5 million.

Second... hopefully the test number for a positive outcome for patients will be disclosed. The necessary minimum number is 7% and hopefully the number will be 15% or greater.

Both of these facts will impact share price in a positive way. Personally, my best guesstimate is that the Canadian share price spikes to at least the 75 cent to $1.00 per share price.
<< Previous
Bullboard Posts
Next >>